EOS Imaging Receives CE Mark for KneeEOS 3-D Planning Software

Paris, France-based EOS Imaging received CE mark for its KneeEOS system, which the company claims is the first 3-D planning software for total knee arthroplasty (TKA) based on EOS bi-planar imaging.

KneeEOS is the second software offering powered by EOS images following HipEOS, which was CE marked and cleared by the U.S. Food and Drug Administration (FDA) in 2014. According to the company, the 3-D surgical planning platform is based on the company’s low-dose 3-D images and technology from OneFit Medical, a company acquired by EOS imaging in late 2013. KneeEOS initially will be deployed as an online service to assist surgeons in patients’ leg alignment simulation in functional position, knee prosthesis selection, and placement simulation based upon 3-D images generated by the EOS system.

“Leg alignment and component positioning are known to significantly influence surgical outcomes for total knee replacement,” said Marie Meynadier, CEO of EOS imaging. KneeEOS is the first and only 3-D planning software for TKA in a functional weight bearing position. We are proud that our work has driven this new development and placed our company at the leading edge of 3-D surgical planning tool innovation that maximizes the potential of EOS’ technology for our surgeon users and their patients. Following the launch of HipEOS and our EOS 3-D Service, KneeEOS marks the continued expansion of our cloud based services based on EOS unique images and associated patient datasets.”

The EOS system provides full-body stereo-radiographic images of patients in functional positions, in both 2-D and 3-D. EOS exams require a radiation dose 50 percent to 85 percent less than digital radiology and 95 percent less than basic computed tomography scans, as well as related software solutions. The new EOS Micro Dose option, recently cleared by the FDA, allows another step—company officials noted—toward the ALARA principle (As Low As Reasonably Achievable) by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.

EOS Imaging develops medical imaging based on technology that enabled George Charpak to win the Nobel Prize for physics, as well as associated solutions. The company is authorized to market in 48 countries, including the United States, Japan and the European Union.  In addition to its office in Paris, the company has four subsidiaries in Besançon, France; Cambridge, Mass.; Montreal, Canada; Frankfurt, Germany; and Singapore.